Compare abrdn Income Credit Strategies Fund (ACP) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Merck & Co., Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Merck & Co., Inc. trades at $125.48 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 485× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | MRK | |
|---|---|---|
Market Cap | $656.21M | $318.26B |
Sector | Financials | Health |
52-Week High | $5.98 | $129.52 |
52-Week Low | $5.01 | $77.60 |
Dividend Yield | 17.78% | 2.64% |
Enterprise Value | — | $361.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Merck (MRK) trades at $126.78, showing stable recent performance with strong institutional interest. The company demonstrates solid fundamentals with 2025 revenue of $65.01B and net income of $18.25B, representing a 28.07% profit margin. Recent earnings have consistently beaten expectations, and the company is actively expanding through strategic acquisitions like Terns Pharmaceuticals. Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators suggest some consolidation may be needed.
Merck presents a compelling investment case with strong profitability, consistent earnings beats, and strategic pipeline expansion through M&A. The stock offers 9.9% upside to the consensus price target of $139.33, supported by 67.6% analyst buy ratings. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The company's robust cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
